PharmaFocus Today – Page 5 – media

Two innovative medical devices were approved for marketing

Recently, the National Medical Products Administration announced the approval of two innovative product registration applications: “Brain Surgery Planning Software” by Beijing Huake Precision Medical Technology Co., Ltd. (hereinafter referred to as Huake Precision) and “Implantable Deep Brain Neurostimulation Extension Lead” by Boston Scientific Neuromodulation Company (hereinafter referred to as Boston Scientific). Huake Precision focuses on the research and development, production and technical services of intelligent and innovative medical devices. It is a leading company in China’s innovative neurosurgery medical devices, providing comprehensive technology and product solutions for the treatment of brain diseases. It is reported that Huake Precision currently has five major product lines including the SR series of neurosurgery robots, the Q300 series of micro neurosurgery robots, the NS series of neurosurgery navigation, the Huake Hengsheng intracranial electrode series, and the LS series of magnetic resonance guided laser ablation treatment systems. It has built a full-chain technology system including ...
- Source: drugdu
- 45
- November 14, 2024
Medicare Fund Prepayment System Introduced, Benefiting Pharmaceutical Sector; Pharmaceutical Stocks Surge

Recently, the National Healthcare Security Administration (NHSA) and the Ministry of Finance released a notice titled “Notice on Effectively Implementing Medicare Fund Prepayment Work” (hereinafter referred to as “the Notice”). This initiative supports certain regions in further improving the management methods for prepayment funds, aiming to alleviate the financial burden of medical expenses for designated medical institutions. It incentivizes these institutions to provide better healthcare services to insured individuals. The announcement led to a significant surge in pharmaceutical stocks yesterday. By the close of trading, companies such as Changyao Holdings, Weikang Pharmaceutical, Guangzheng Ophthalmology, and Wanbangde had hit their daily limit, while Lukang Pharmaceutical and Purui Ophthalmology also saw substantial gains. It’s noteworthy that the stocks that surged included a variety of sectors, spanning specialized hospitals and pharmaceutical companies. The CSI Medical Index rose by 1.2%, the CSI 300 Medical and Health Index increased by 0.97%, and the CSI Innovative ...
- Source: drugdu
- 33
- November 14, 2024
Innovative Drug Leader Breaks $1 Billion in Quarterly Revenue for the First Time

Last night, BeiGene Ltd, a leader in innovative pharmaceuticals, released its third-quarter report for 2024. The company achieved operating revenue of 7.139 billion yuan (approximately $1.03 billion), marking a year-on-year increase of 26.9%. However, the net profit attributable to the parent company reported a loss of 809 million yuan, a decline of 160.4% compared to the same period last year. This marks the first time the company’s quarterly revenue has exceeded $1 billion. BeiGene attributed the increase in third-quarter revenue primarily to higher product sales compared to the same period last year. The decrease in net profit, on the other hand, was mainly due to a non-cash gain recognized from a settlement with Bristol-Myers Squibb (BMS) in the previous year. It is worth noting that in the financial data for the first three quarters, the company has faced pressure in cash flow management, recording a net cash flow from operating ...
- Source: drugdu
- 33
- November 14, 2024
AstraZeneca’s Global CEO Responds for the First Time to the Detention of Chinese Executive

On November 12, local time, Pascal Soriot, the Global CEO of AstraZeneca, publicly responded for the first time to the detention of the company’s China President, Wang Lei. Soriot stated, “Wang Lei is discussing the matter with his lawyer, and the company does not have any new information regarding the case.” Soriot made these comments following the release of AstraZeneca’s third-quarter financial report. He emphasized, “We take issues related to the Chinese market very seriously and are taking measures to enhance compliance.” However, he denied that AstraZeneca’s headquarters lacked oversight on compliance matters. He noted that the company has over 16,000 employees in China and lamented that some individuals may succumb to “temptation” to maximize sales. Moreover, he mentioned that AstraZeneca has strengthened its compliance team in China, which consists of over 200 members, and has introduced resident compliance officers who use artificial intelligence to review expense reports from sales ...
- Source: drugdu
- 38
- November 14, 2024
Seizing the “Golden Race” of Synthetic Biology

On November 8th, Hangzhou, Zhejiang Province held a conference on the high-quality development of the synthetic biology industry and released the “Three Year Action Plan for the High Quality Development of the Synthetic Biology Industry in Hangzhou (2024-2026)” (hereinafter referred to as the “Three Year Action Plan”). According to the “Three Year Action Plan”, Hangzhou aims to implement five major actions, including breakthroughs in core technology, upgrading of platform capabilities, cultivation of enterprise tiers, strengthening of industrial clusters, and optimization of industrial ecology. The goal is to achieve a total output value of 40 billion yuan in the city’s synthetic biomanufacturing industry by 2026. According to incomplete statistics, Hangzhou currently has more than 260 synthetic biology related enterprises, with a production value of over 25 billion yuan by 2023. Shen Kaibo, Deputy Secretary General of Hangzhou Municipal Government, stated that with the release of the “Three Year Action Plan”, Hangzhou ...
- Source: drugdu
- 52
- November 13, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 51
- November 13, 2024
Imaging giant, newly established production base

Recently, Yum! Brands announced the establishment of a new manufacturing base (B-15, Sector 60 Noida Uttar Pradesh) in New Delhi, created and managed by its subsidiary Esaote Asia Pacific Diagnostic Private Limited, to further strengthen its business in India. Yum! Brands’ new production base will produce a full range of “Made in India” advanced ultrasound products for the Indian market, including My Lab ™ A、My Lab ™ E Series and compact portable ultrasound devices will be launched on the market shortly after completing regulatory and quality assurance processes with local authorities. Data shows that Yum! Brands is headquartered in Italy, with its main research and development production bases located in Italy, as well as production bases in the Netherlands and China. In the field of ultrasound imaging, Baisheng Medical Group has mastered the core technology of the entire industry chain and has the ability to independently develop core components. It ...
- Source: drugdu
- 51
- November 13, 2024
Three types of consumables will be purchased upon expiration

Hefei is soliciting opinions on the continuous procurement of three types of medical consumables, and the centralized procurement of consumables in prefecture level cities continues to accelerate. 3 types of consumables, with purchase renewal upon expiration On November 7th, the Medical Security Bureau of Hefei City solicited opinions on the draft of the “HFHCDC-2024-1 Concentrated Procurement Document for Some Medical Consumables in Hefei City” (hereinafter referred to as the “Draft for Comments”), which will soon start the continuous procurement work for three types of medical consumables. The specific procurement varieties and related requirements are as follows: According to the draft for soliciting opinions, the actual purchase quantity of selected products in each medical institution shall not be less than 80% of the total purchase quantity of the same variety. The procurement entity for this continuation of procurement work is public medical institutions in Hefei city. The proposed selection rules are ...
- Source: drugdu
- 54
- November 13, 2024
Just now! The National Medical Insurance Administration and the Ministry of Finance issued a document to solve the difficulty of collecting payments!

On November 11, the “Notice of the Office of the National Medical Insurance Administration and the General Office of the Ministry of Finance on Doing a Good Job in Prepayment of Medical Insurance Funds” (full text attached at the end of the article) was officially released. According to the notice, in principle, the prepayment is based on the average monthly expenditure of the relevant medical insurance funds in the previous one to three years, and the basic scale is determined, and adjusted in combination with the annual comprehensive evaluation and credit evaluation of designated medical institutions. The prepayment scale is about 1 month. The document clearly stipulates that medical insurance prepayments shall not be used for non-medical expenses such as medical institution infrastructure investment, daily operation, and debt repayment. The special prepayment of medical insurance funds for centralized volume procurement of drugs and medical consumables shall be implemented in accordance ...
- Source: drugdu
- 48
- November 13, 2024
1.82 billion, “China Resources” adds another member

On November 8, China Resources Boya Bio’s official website announced that “China Resources Boya Bio and Green Cross (China) meeting and work docking meeting were successfully held”. Two days ago (November 6), China Resources Boya Bio completed the acquisition of 100% equity of Green Cross (Hong Kong) and began to include it in the scope of consolidated financial statements. So far, “China Resources” has officially made another move in the blood products sector. In July this year, China Resources Boya Bio agreed to transfer 100% equity of Green Cross (Hong Kong) with its own funds of 1.82 billion yuan, thereby indirectly acquiring the domestic blood products entity Green Cross (China) (for details, please refer to the previous article “Spending 1.82 billion! China Resources Group takes action again”). As the blood products platform of China Resources’ big health sector, China Resources Boya Bio’s contribution to China Resources Pharmaceutical’s performance cannot be ...
- Source: drugdu
- 47
- November 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.